Staar Surgical's stock jumped today (May 16), despite revenue struggles amid weak demand in China, a positive signal for the company is the company's positive signal for the company, after the implantable lens developer revealed plans to bring $30 million worth of stock back to ownership.
Based in the U.S., Starar, its board of directors authorized today's outstanding common stock repurchase program, saying that the timing, method and price of any transaction will be at its discretion. As of March 2025, Starar owns approximately 49.5 million common shares in circulation.
After the announcement, shares of Nasdaq listed companies rose 5% on May 16 to $19.25, which opened on May 16. Starar has a market capitalization of $906 million.
Staar may purchase shares on the open market through privately negotiated transactions or to enter into a structured repurchase agreement with third parties.
Buying blocks that involves buying large amounts of stocks to avoid market price fluctuations may also be a way to go. Starr said the route is to go hand in hand with Rule 10B5-1 trading plan - a regulation that allows company insiders to trade stocks without violating trading laws.
Starar said it may modify or suspend the plan at any time, although it is currently planning to continue the plan over the next six months.
Repurchase shares is a way for companies with auxiliary cash to increase their earnings per share. It also increases the value of the remaining stock and adjusts the voting rights. However, the size and nature of the repurchase depends on the company's reserve.
Staar said the stock buyback will be funded by cash on hand and cash generated from operations. As of March 2025, the company had a request of $222.8 million.
Share repurchases have become a popular trend in 2025, as companies hope to increase their ownership shares in an uncertain macroeconomic climate. In the pharmaceutical industry, Sanofi implemented a $5.1 billion stock buyback program in 2025.
"Our decision to initiate a stock buyback program highlights the board and management's confidence in Staar's future and our ability to return to sustainable, profitable growth," said Stephen C Farrell, CEO of Starar Surgical.
Starar fought revenue in 2024, releasing only $49 million for the whole year, down from $76.3 million in 2023. In government initiatives that affect equipment procurement, the company blames “a significant decline in China’s revenue.” This is a question that affects a wide range of players in the MedTech industry. Philips, for example, continues to expect softer demand for products in the region this year.
Starar's product line is called EVO, with various brands of myopia, astigmatism and hyperopia. These devices are implantable collision lenses (ICLs) performed during surgical procedures and provide long-term corrections to vision. Although more expensive, reversible ICLs provide an alternative to laser-assisted approaches for people who are not suitable for laser surgery or those who do not want to permanently change their eyes.
According to GlobalData's analysis, the global intraocular lens equipment market is expected to grow to US$5.6 billion by 2034, up from US$4.5 billion in 2024. Starar is estimated to account for 1.8% of global market share.
“Despite the difficulties in the Chinese market, despite the difficulties in the Chinese market, the “Staar Surgical Program’s $30 million share buyback” was originally created and published by GlobalData-owned brand Medical Device Network.
The information on this website is included in sincerity only for general information purposes. It is not intended to rely on the advice you should rely on, and we do not provide any representation, warranty or warranty that express or imply its accuracy or completeness. You must take or avoid any action based on the content on our website to obtain professional or professional advice.